Regulation of phage therapy medicinal products: developments, challenges, and opportunities.

Fuerst-Wilmes M, Respondek V, Schramm M, Lilienthal N, Buss K, Duechting A

Open source

DOI
10.3389/fcimb.2025.1631359
Published
2025
Container
Frontiers in cellular and infection microbiology
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.3389/fcimb.2025.1631359,
  title = {Regulation of phage therapy medicinal products: developments, challenges, and opportunities.},
  author = {Fuerst-Wilmes M and Respondek V and Schramm M and Lilienthal N and Buss K and Duechting A},
  year = {2025},
  journal = {Frontiers in cellular and infection microbiology},
  doi = {10.3389/fcimb.2025.1631359},
  url = {https://doi.org/10.3389/fcimb.2025.1631359}
}

RIS

TY  - JOUR
TI  - Regulation of phage therapy medicinal products: developments, challenges, and opportunities.
AU  - Fuerst-Wilmes M
AU  - Respondek V
AU  - Schramm M
AU  - Lilienthal N
AU  - Buss K
AU  - Duechting A
PY  - 2025
JO  - Frontiers in cellular and infection microbiology
DO  - 10.3389/fcimb.2025.1631359
UR  - https://doi.org/10.3389/fcimb.2025.1631359
ER  - 

APA

M, F., V, R., M, S., N, L., K, B., & A, D. (2025). Regulation of phage therapy medicinal products: developments, challenges, and opportunities.. Frontiers in cellular and infection microbiology. https://doi.org/10.3389/fcimb.2025.1631359

Source records